This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Concordia Healthcare Corp.
Drug Names(s): Jenloga Twice Daily, clonidine hydrochloride modified or extended release, Clonicel/Sympres, CloniBID
Description: BioMedTracker has a separate entry for Jenloga XR, a once-daily formulation being developed for hypertension, but reportedly not for ADHD.
Kapvay/Jenloga extended release is a twice daily modified release formulation of clonidine hydrochloride. Kapvay is the brand name for the ADHD indication, and Jenloga for hypertension. While the immediate release formulation of clonidine is also given twice daily, the maximum concentration of Kapvay is a little over half that for the immediate release. Clonidine hydrochloride is a centrally acting alpha-2 agonist.
Deal Structure: In July 2007, Sciele Pharma announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals to market, upon approval by the U.S. Food & Drug Administration (FDA), CLONICEL. Sciele will also have the right of first refusal for other Addrenex products focused on pediatrics, women's health, and cardiovascular/metabolic diseases. Under the terms of the agreement, Sciele has purchased a $6 million equity stake in Addrenex and will have the right to increase its equity stake in Addrenex by an additional 10%. Sciele will also make regulatory milestone payments of up to $11 million and royalty payments to Addrenex on product sales.
In September 2008, Shionogi & Co. and Sciele Pharma announced that they entered into a definitive agreement under which Shionogi & Co. will acquire Sciele Pharma. Under the terms of agreement and pursuant to a tender offer, Shionogi will acquire all the outstanding shares of Sciele's common stock at a price of $31 per share, for a total equity...See full deal structure in Biomedtracker
Partners: Shionogi & Co. Ltd.
Pink Sheet February Supplemental Approvals
Pink Sheet September 2010 Supplements
Additional information available to subscribers only: